Summit Therapeutics rises after AstraZeneca commits $2B investment (SMMT:NASDAQ)
· seekingalpha.com
Summit (SMMT) and AstraZeneca (AZN) ink a $2B convertible investment plus GI cancer trial collaboration for ivonescimab/ADCs—read key terms now.
Summit (SMMT) and AstraZeneca (ANZ) announced on Monday that the companies have entered into an agreement whereby AstraZeneca will make an equity investment of ...